Levi & Korsinsky, LLP announces that a YMAB class action lawsuit has been filed on behalf of investors who purchased Y-mAbs Therapeutics, Inc. (YMAB)This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020, through October 28, 2022, For more on the YMAB Lawsuit please contact us today.

According to the Y-mAbs lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Y-mAbs misrepresented the U.S. Food and Drug Administration’s (“FDA”) willingness to approve omburtamab, the Company’s lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA’s requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit March 31, 2022, Biologics License Application prior to reaching an agreement with the FDA on the content of the application.

TO LEARN MORE ABOUT THE YMAB CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Y-mAbs you have until March 20, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com